Medherant is a clinical-stage pharmaceutical company developing innovative transdermal therapies using its proprietary TEPI Patch® technology; a novel, patented platform designed for safe, effective and convenient drug delivery through the skin.
Transdermal drug delivery offers key advantages over oral administration, including more stable drug levels, fewer side effects and improved patient compliance. Compared to gels and creams, patches are more convenient and provide better dose control.
The company’s lead product is a testosterone patch treating Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women, a significant unmet need.
In a Phase I pharmacokinetic study, the patch demonstrated excellent tolerability and predictable dose-ranging performance with both pilot and optimised formulations.
Central to the TEPI Patch® platform is a proprietary pressure sensitive adhesive, developed by Medherant. The drug is mixed directly into the adhesive, enabling consistent and controlled release.
Medherant was founded by Professor David Haddleton and the University of Warwick using their world-leading expertise in bioadhesives and polymer chemistry.
In addition to developing its own transdermal and topical products, Medherant is collaborating with third parties to formulate their drugs for transdermal delivery using its TEPI technology. In the future, Medherant expects to receive milestone payments and/or licence revenues for products utilising its technology.
Medherant has secured funding from Mercia Fund Management, British Business Bank and private investors.